Literature DB >> 2423709

The role of transabdominal ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy.

C G Roehrborn, H K Chinn, P F Fulgham, K L Simpkins, P C Peters.   

Abstract

We evaluated 59 consecutive patients for obstructive voiding symptoms with physical examination, excretory urography, urethrocystoscopy, post-voiding residual volumes, uroflowmetry and transabdominal ultrasound of the prostate. Of the patients 53 underwent transurethral resection of the prostate and 6 underwent open prostatectomy. Followup uroflowmetry was done 4 weeks postoperatively. The best predictor of the actual prostatic weight was transabdominal ultrasound (r equals 0.975), and with digital rectal examination and urethrocystoscopy there was a tendency to overestimate small and underestimate large glands. Symptoms such as nocturia do not allow any conclusions about the size of the prostate. The correlation between post-void residual and specimen weight also is poor and only patients in retention (Foley catheter) have a significantly larger prostate. Preoperative uroflowmetry provides limited information about the prostatic size but, although the difference between the preoperative and postoperative flow rate index is highly significant (p less than 0.001, mean difference test), the correlation between specimen weight, and the difference between preoperative and postoperative flow rate index is not significant. We recommend transabdominal sonography of the prostate, a simple and noninvasive procedure, as a useful adjunct in the preoperative evaluation of patients with benign prostatic hypertrophy. In addition to the fact that only this method provides reliable and reproducible estimations of the weight of the prostate, further information, such as measurement of the post-void residual volume, can be obtained without additional costs or loss of time.

Entities:  

Mesh:

Year:  1986        PMID: 2423709     DOI: 10.1016/s0022-5347(17)46032-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

Review 1.  Benign prostatic hyperplasia and its treatment.

Authors:  J B Stimson; S D Fihn
Journal:  J Gen Intern Med       Date:  1990 Mar-Apr       Impact factor: 5.128

2.  [Diagnostic and differential diagnosis of benign prostate syndrome (BPS): guidelines of the German Urologists].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

3.  Clinical and retrospective evaluation of Eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia.

Authors:  M Ishigooka; T Hashimoto; S Hayami; M Tomaru; T Nakada; K Mitobe
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 4.  [Diagnostics of benign prostate syndrome].

Authors:  M Seitz; A Herlemann; G Magistro; C G Stief
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

5.  Value of routine renal and abdominal ultrasonography in patients undergoing prostatectomy.

Authors:  Muhammad Rafique
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

6.  Office evaluation of male patients with lower urinary tract symptoms.

Authors:  Shahin Tabatabaei; Saman Shafaat Talab; Mahdi Zangi; Henry H Woo
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

7.  A comparison between transabdominal ultrasonographic and cystourethroscopy findings in adult Sudanese patients presenting with haematuria.

Authors:  Feras O Ahmed; Hamdan Z Hamdan; Hani B Abdelgalil; Abdulrauf A Sharfi
Journal:  Int Urol Nephrol       Date:  2014-11-06       Impact factor: 2.370

8.  Usefulness of non-invasive diagnostic methods for early detection of neoplasms of the urinary tract and male genitals among workers of the Mazovian Refining and Petrochemical Plant in Płock.

Authors:  A Majek; E Miekoś
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

9.  Effect of the alpha-1 adrenoceptor blocker on tissue norepinephrine contents in human benign prostatic hyperplasia.

Authors:  M Ishigooka; S Hayami; T Hashimoto; Y Suzuki; O Ichiyanagi; T Nakada
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

10.  Norepinephrine contents of human prostatic hyperplasia: differences between pathological subtypes.

Authors:  M Ishigooka; S Hayami; M Tomaru; T Hashimoto; I Sasagawa; T Nakada
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.